Press release
Computed Tomography to Drive The Orally Disintegrating Tablet Market
Improvements in drug delivery mechanism offering quicker onset of action with superior bioavailability per dose have transformed characteristics of orally administered drugs with the development of orally disintegrating tablets (ODTs). The global orally disintegrating tablets market was valued at nearly US$ 12 Bn in 2018 and will exhibit a solid CAGR during the forecast period (2019 - 2029).
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/14572
There has been growing preference among consumers and patients for orally disintegrating tablets attributed to increasing applications in treatment of diseases related to central nervous system (CNS), gastrointestinal (GI), cardiovascular disorders, and allergy. Bayer's acquisition of Merck's consumer care unit was aimed at gaining shares in ODTs. Claritin, an ODT received through this acquisition, was the largest revenue generating drug for allergy in the U.S. that year.
Company Profiles:
Teva Pharmaceutical Industries Ltd.
Novartis AG
AstraZeneca
Mylan N.V.
Pfizer Inc.
Johnson & Johnson Services, Inc.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Bausch Health
GlaxoSmithKline plc.
Sun Pharmaceutical Industries Ltd.
Bayer AG
Eli Lily and Company
Dr. Reddy's Laboratories Ltd.
Takeda Pharmaceutical Company Limited
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/14572
Key Takeaways - Orally Disintegrating Tablets Market Study
CNS diseases remain the primary area of application for orally disintegrating tablets. Researchers and healthcare providers are increasingly focusing on medical conditions such as encephalitis, autism, Alzheimer's disease, schizophrenia, depressive disorders and others to increase the application of orally disintegrating tablets.
Formulation process of orally disintegrating tablets is usually patented by manufacturers depending on the technology employed during the production such as lyophilization, freeze drying, and floss formation. Many technologies such as ZYDIS®, LYOC® and QUICKSOLV® are dependent on freeze drying method.
Easy disintegration of orally disintegrating tablets in saliva within a few seconds and accuracy of dose as compared to liquid forms and chewable tablet are expected to increase the adoption of ODTs in diseases such as ulcers of throat.
Attributed to consumers facing swallowing problems, bitter taste of drugs, and patient incompliance, manufacturers are focusing to improve drug formulations. This would help them gain an edge in terms of innovation, further favoring the growth of orally disintegrating tablets market.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/14572
Key Manufacturers Exploring New Business Models
The global orally disintegrating tablets market is fragmented with low entry barriers inspiring generic manufacturers to tap market opportunities in the form of ANDA, arising from the expiry of patent regime of approved drugs. For instance, Mylan N.V. launched Lansoprazole DR ODT, a generic version of Takeda's Prevacid® SoluTab DR ODT. The entry of The Himalaya Drug Company LTD. and Banyan Botanicals with new herbal ODT product offerings in next few years is expected to increase product lines and extension in ODTs market.
Complete Report Details@ https://www.persistencemarketresearch.com/market-research/orally-disintegrating-tablet-market.asp
Report Inclusions
Persistence Market Research offers a unique perspective and actionable insights on the Orally Disintegrating Tablets landscape in its new study, presenting historical demand assessment from 2014 - 2018 and projections from 2019 - 2029 on the basis of drug class (anti-psychotics, anti-epileptics, CNS stimulants, anxiolytics, anti-Parkinsonian drugs, anti-hypertensives, NSAIDS, anti-allergy drugs, proton pump inhibitors), disease indication (CNS diseases, GI diseases, allergy, CVS disorders), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online pharmacies), and five key regions.
Related Reports:
Allergy Shots Market - https://www.persistencemarketresearch.com/market-research/allergy-shots-market.asp
Uveitis Treatment Market - https://www.persistencemarketresearch.com/market-research/uveitis-treatment-market.asp
Contact Us:
Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com
About Us:
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Computed Tomography to Drive The Orally Disintegrating Tablet Market here
News-ID: 2559735 • Views: …
More Releases from Persistence Market Research
Krill Oil Market to Hit US$465.0 Mn by 2033 Driven by Omega-3 Demand
The global krill oil market is poised for substantial expansion, reflecting growing consumer awareness regarding preventive healthcare and the rising demand for omega-3 supplements derived from sustainable marine sources. Valued at approximately US$210.2 million by 2026, the market is projected to register a robust compound annual growth rate (CAGR) of 12.0% during the forecast period, ultimately reaching an estimated US$465.0 million by 2033. This growth trajectory underscores the increasing preference…
Non-Alcoholic Beer Market to Hit US$42.3 Billion by 2033 Driven by Health Trends
The global non-alcoholic beer market is poised for robust expansion, reflecting a significant shift in consumer preferences toward healthier and mindful drinking alternatives. The market size is estimated to reach US$ 25.5 billion in 2026 and is projected to grow to approximately US$ 42.3 billion by 2033, registering a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2026-2033. This growth trajectory underscores the increasing acceptance of…
Foaming Agents Market to Achieve US$ 10.6 Billion by 2033 at a CAGR of 6.8% - Pe …
The global foaming agents market is witnessing steady and transformative growth, fueled by increasing demand across a wide spectrum of industries. According to the latest study by Persistence Market Research, the market is projected to grow from US$ 6.7 billion in 2026 to US$ 10.6 billion by 2033, registering a CAGR of 6.8% during the forecast period. This upward trajectory is primarily driven by the rising need for high-performance foam…
Industrial Salt Market to Grow to US$ 23.6 Billion by 2033 at a CAGR of 5.8%- Pe …
The global industrial salt market is entering a phase of steady expansion, supported by its indispensable role across multiple industries. According to the latest study by Persistence Market Research, the market is projected to grow from US$ 15.9 billion in 2026 to US$ 23.6 billion by 2033, registering a CAGR of 5.8% during the forecast period. A major factor underpinning this growth is the strong demand from chemical manufacturing, particularly…
More Releases for ODT
Orally Disintegrating Tablet (ODT) Market Analysis, Size, Current Scenario and F …
Orally disintegrating tablet (ODT) market is anticipated to grow at a significant CAGR during the forecast period. According to the US Food and Drug Administration (FDA), ODT's are a solid dosage form that contains a medicinal substance or active ingredient which rapidly disintegrates when placed upon the tongue within a second. The major factor for the growth of the global orally disintegrating tablet (ODT) market during the forecast period is…
Orally Disintegrating Tablet (ODT) Market Share 2021 Growth Challenges, Opportun …
The global orally disintegrating tablet (ODT) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). According to the US Food and Drug Administration (FDA), ODT’s are a solid dosage form that contains a medicinal substance or active ingredient which rapidly disintegrates when placed upon the tongue within a second. The major factor for the growth of the global orally disintegrating tablet (ODT) market during the…
Orally Dissolving Tablets (ODT) Excipient Market global outlook and forecast 202 …
The Global Orally Dissolving Tablets (ODT) Excipient Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Orally Dissolving Tablets (ODT) Excipient makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and…
Investigation announced for Long-Term Investors in shares of Odonate Therapeutic …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Odonate Therapeutics, Inc..
Investors who are current long term investors in Odonate Therapeutics, Inc. (NASDAQ: ODT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ODT stocks follows a lawsuit filed against Odonate…
Deadline on Nov. 16th coming up in Lawsuit for Investors in Odonate Therapeutics …
The Shareholders Foundation announced that a deadline is coming up on November 16, 2020 in the lawsuit filed for certain investors of Odonate Therapeutics, Inc. (NASDAQ: ODT) over alleged securities laws violations by Odonate Therapeutics, Inc.
Investors who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and there are strict and short deadlines running. Deadline: November 16, 2020. NASDAQ: ODT stockholders should contact the Shareholders Foundation at…
Lawsuit filed for Investors in shares of Odonate Therapeutics, Inc. (NASDAQ: ODT …
An investor, who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT), filed a lawsuit over alleged Securities Laws violations by Odonate Therapeutics, Inc.
Investors who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 16, 2020. NASDAQ: ODT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
San Diego, CA based Odonate Therapeutics,…
